- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01253980
Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
The Efficacy of Prophylactic Antibiotics in the Management of Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The average of 100 children per annum attending Red Cross War Memorial Children's Hospital 9RCWMCH) with the diagnosis of kerosene ingestion would give a sample of 200 children over a two-year period, with 100 patients in each group. From a postulated secondary infection rate of 15 to 50% for children not receiving an antibiotic, a midway point of 25% estimated the treatment failure rate in the placebo group. With no information available on the treatment failure rate in the active group, failure rates of 10% and 5% were arbitrarily applied. With 25% and 5% treatment failure rates for placebo and active groups respectively, at a level of significance of α = 0.05 a sample size of 100 per group gives a power of 0.98 and with failure rates of 25% and 10% a power of 0.80.
Statistical analysis was done using IBM SPSS Version 20 (SPSS Inc., Chicago, IL, USA). Categorical variables are expressed as n (%) and continuous variables as median (interquartile range (IQR)). A P value of ≤ 0.05 was considered significant for all situations. For categorical variables, Fischer's exact test was used for small samples or less frequent occurrences. Chi-Square testing was applied for larger samples or more frequent occurrences. Mann-Whitney or Kruskal-Wallis tests were used for ordinal and continuous variables. Significant correlation between factors and covariates (Spearman's rank coefficient) favoured univariate analysis over binary logistic regression modelling to determine potential risk factors for treatment failure. Continuous variables were categorised for clinical relevance or logistic regression testing. In some instances, specific clinical parameters or reported symptoms were not recorded or the presence or absence of a risk factor was unknown. The missing values, unknown factors and the flow of patient follow-up account for totals not always adding up to the full number of study participants. In the results for Day 3 and Day 5 post-ingestion, the denominator used to calculate proportions for reported symptoms included those patients who attended and who were telephone interviewed, whereas the denominator for clinical signs was only the patients who attended.
The primary outcome measure was treatment failure, as reported. Secondary outcome measures were length of hospital stay, reported symptoms (cough, shortness of breath, wheeze and fever) and clinical signs (respiratory rate, flaring, recessions, grunting, wheeze, crepitations, temperature and altered mental status) at follow-up at Day 3 and 5 post-ingestion for placebo and active groups. Further investigation explored the role of confounding conditions (upper respiratory tract infection, active Mycobacterium tuberculosis infection) and risk factors for treatment failure or delayed resolution (vomiting post-ingestion, household smoking contact, HIV exposure status, prior respiratory history, young age etc). Secondary outcome measures, confounding conditions and risk factors are not reported in this Clinical Trials format, but are reported in the PI's Master's thesis. (Balme KH. The efficacy of prophylactic antibiotics in the management of pneumonitis following paraffin (kerosene) ingestion in children [Master's thesis]. [Cape Town]: University of Cape Town; 2013. 113 p.)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7700
- Red Cross War Memorial Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ingestion in the preceding 24 hours
- Presence of respiratory symptoms and/or signs at presentation
- Informed consent obtained from parent or legal guardian
- Resident within the Red Cross Hospital drainage area and able to come for two follow-up appointments
Exclusion Criteria:
- Asymptomatic and no clinical signs
Too ill to be excluded from receiving an antibiotic as judged by:
- Requiring more than 2L/min nasal-prong oxygen
- Requiring continuous or intermittent positive airway pressure ventilation
- Fever > 40˚C
- Needing an antibiotic for another reason e.g. otitis media, tonsillitis
- Current antibiotic use, prior to kerosene ingestion
- Allergic to amoxicillin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Amoxicillin
|
Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
|
Placebo Comparator: Placebo suspension
Placebo
|
Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator. Dose 20-30mg/kg 8 hourly for 5 days |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Failure
Time Frame: At routine follow-up 3 and 5 days post-ingestion or earlier if necessary
|
A treatment failure was a patient who at any time deteriorated necessitating a change to the treatment regimen.
This was determined by assessing reported symptoms (cough, shortness of breath, wheeze and fever) and comparing clinical signs (respiratory rate, oxygen saturation, wheeze, flaring, grunting, recessions, crepitations, temperature, mental status) to signs at presentation.
|
At routine follow-up 3 and 5 days post-ingestion or earlier if necessary
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Heather Zar, MBBCh PhD, University of Cape Town
- Study Director: Michael D Mann, MMed Paed PhD, University of Cape Town
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 095/2010
- PACTR201201000259370 (Registry Identifier: Pan African Clinical Trial Registry)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kerosene Pneumonitis
-
Peking Union Medical College HospitalRecruitingSevere Checkpoint Inhibitor PneumonitisChina
-
Royal Brompton & Harefield NHS Foundation TrustUniversity of Nottingham; GlaxoSmithKline; University College, LondonCompletedIdiopathic Pulmonary Fibrosis | Idiopathic Non-specific Interstitial PneumonitisUnited Kingdom
-
Human AdamsAmsterdam UMC, location VUmcCompletedLung Diseases, Interstitial | Pneumonitis, InterstitialNetherlands
-
University of California, Los AngelesRecruitingPulmonary Fibrosis | Pneumoconiosis | Interstitial Lung Disease | Idiopathic Interstitial Pneumonias | Radiation Pneumonitis | Hypersensitivity Pneumonitis | Drug-Induced PneumonitisUnited States
-
Centre Hospitalier Universitaire de BesanconCompletedAvian Hypersensitivity PneumonitisFrance
-
Xinqiao Hospital of ChongqingRecruiting
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)TerminatedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Steroid-Refractory PneumonitisUnited States
-
Instituto Nacional de Cancerologia de MexicoNational Council of Science and Technology, MexicoCompletedRadiation; Adverse Effect, PneumonitisMexico
-
Taipei Medical University WanFang HospitalUnknown
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenRecruitingImmunotherapy | Pneumonitis, Interstitial | Immune-related Adverse EventsBelgium
Clinical Trials on Amoxicillin
-
Universita degli Studi di GenovaNot yet recruiting
-
Saskatchewan Health Authority - Regina AreaNot yet recruiting
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedPostpartum Sepsis | Postpartum Endometritis | Postpartum FeverCameroon
-
Malmö UniversityCompletedAntibiotic Prophylaxis | Infection ControlSweden
-
University Medical Centre LjubljanaUniversity of Ljubljana School of Medicine, SloveniaRecruiting
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompletedHelicobacter Pylori Eradication RateChina
-
Assistance Publique - Hôpitaux de ParisCompletedChronic Obstructive Lung Disease (COLD)France
-
Ranbaxy Laboratories LimitedCompletedHealthyUnited States
-
Klara Posfay-BarbeGertrude Von Meissner Foundation; Recherche et Développement des HUG; Société...UnknownGroup A Streptococcal PharyngitisSwitzerland
-
University Hospital, Clermont-FerrandUnknown